Longitudinal mapping of responses, relapses, and cytogenetic progression. All enrolled patients are shown, grouped into responders and nonresponders at the primary end point of 16 to 20 weeks. From baseline until the primary end point or early discontinuation due to intolerance (UPN27), all patients were taking EPAG, designated by gray bars. Seventeen patients met hematologic response criteria at the primary end point and were continued on EPAG on the extension arm of the study, designated by solid green bars. Twelve of 17 patients reached robust or stable response criteria (see the Methods section) and were taken off EPAG (hatched green bars). Seven of these patients relapsed after EPAG was discontinued; EPAG was restarted, and all of them again responded (solid yellow bars). Four patients again reached a robust response and came off EPAG a second time (hatched yellow bars). The 2 patients with cytogenetic progression are shown with the specific chromosomal change and the number of abnormal metaphases. The 3 patients with germline mutations are indicated (TERT, RPS19, and MPL).